Multi-Market Compliance Matrix: Set the Route Before Artwork
Emerging exosome brands meet overlapping frameworks the hard way — after packaging prints. This playbook writes the compliance matrix per program before art development. — a written compliance matrix per program is the way to launch multi-market without legal surprises.
01 · The problem
One exosome program can be three different regulated products: a cosmetic in the EU and US, a supplement in some oral formats, a professional-use product in clinic channels. Each carries its own filing, claims boundary and documentation set. Brands discover this after packaging is printed. The fix is a compliance matrix written per program before art development, and maintained as markets shift.
02 · Scientific rationale
The matrix maps each program's positioning to destination-market frameworks: EU cosmetic (Reg. 1223/2009 + CPNP), US cosmetic (MoCRA), US oral (DSHEA), EU oral (food supplement / novel food), professional-use channels (clinic or veterinary). Claims are set per route: appearance-level for cosmetics, structure/function-style for US supplements, permitted-claims lists for the EU. One batch documentation system serves all of them.
03 · Program documentation
The matrix methodology follows TONGNIAN's internal compliance process files; national-standard drafting participation anchors the measurement definitions [6].
Method anchors: [1] EV biology and cargo [2] MISEV2018 characterization [3] category evidence (review or registered study) [4] formulation and handling guidance [5] national measurement guideline (2026 No. 17) [6] internal protocol and case documentation.
04 · Product architecture
| Route | Framework | Claims boundary |
|---|---|---|
| Cosmetic (EU/US) | 1223/2009 + CPNP; MoCRA | Appearance & feel |
| Oral (US) | DSHEA supplement | Structure/function-style |
| Oral (EU) | Food supplement / novel food | Permitted claims |
| Professional | Channel rules vary by market | Professional use only |
05 · Process & QC
Each program ships with its completed matrix row: route, claims boundary, documentation set. Marketing signs off on the matrix row before any artwork is built; the gate runs pre-press.
Fig. 1 — The compliance matrix: four routes, one batch system.
06 · Regulatory pathway: EU & US first
EU/US first by design; China CSAR/health-food routes are additional-market rows on the same matrix.
07 · Expected outcomes
- **Multi-market launches run off one batch system — claim discipline fixed before packaging, legal surprises designed out.erves every route.
- Claim discipline set before packaging, not after.
No claims beyond the destination-market framing — authority comes from documentation and batch measurement.
08 · Commercial framework
Sample kits in 3-5 days; pilot from 500 units; production from 2,000 units; standard lead 15 workdays - all indicative, quoted per request. White-label and program naming run through the OBM program.
Request a quote - Line fact-sheet per program page.
References
- Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977.
- Théry C, et al. MISEV2018. J Extracell Vesicles. 2018;7(1):1535750.
- Guideline for Exosome Particle Size and Concentration Measurement (2026 No. 17) — TONGNIAN, drafting organization.
- TONGNIAN internal process documentation — closed-line SOPs, QC panels, batch records (partner access under NDA).
Apply this playbook to your category
Submit your brand stage, target category, and target volume tier to receive specifications, MOQ, and lead-time quotes for the matching tier (quotation follows the tier structure).